Do Checkpoint Inhibitors Really Work in Myeloma?

This is another paper that sort of caught my eye from the last ash meeting in December. I don't hear too much about checkpoint inhibitors outside of Hodgkin and hemologic cancers. This was an interesting idea of using Novolomab salvage therapy in patients who relapse after CAR-T. It didn't work in everybody, Neil. But if you have exhaustion markers on those T cells, we were able to restore responses in a couple of patients,. albeit for a short period of time.